CURRICULUM VITAE

Shahram “Shawn” Yazdani, MD, FACC, FSCAI

Professional Experience

2018 – present
Carient Heart & Vascular, Senior Partner and Interventional Cardiologist

2016 – 2018
Interventional Co-Director, Inova Structural Heart Program

2015 – 2018
Director of CTO and Complex Coronary Intervention,
Inova Health Care Services – Inova Cardiology; Falls Church, VA

2000 – 2015
Carient Heart & Vascular (formerly Virginia Cardiovascular Associates),
Senior Partner, Interventional Cardiologist, Manassas, VA

1998 – 2000
Premier Heart Specialists, Interventional Cardiologist

Hospital Affiliations

2000 – present:

  • Novant Prince William Medical Center, Manassas, VA, Dept. of Medicine, Cardiology
  • Inova Fairfax Hospital, Falls Church, VA, Dept. of Medicine, Cardiology
  • Inova Fair Oaks Hospital, Fairfax, VA, Dept. of Medicine, Cardiology
  • Fauquier Hospital, Warrenton, VA, Dept. of Medicine, Cardiology

1998 – 2000:

  • Easton Hospital, Easton, PA, Dept. of Medicine, Cardiology
  • Warren Hospital, Phillipsburg, NJ, Dept. of Medicine, Cardiology
  • St. Luke’s Hospital, Bethlehem, PA, Dept. of Medicine, Cardiology

Education

9/87 – 5/91: M.D. New York University School of Medicine
9/83 – 6/87: B.A. New York University

Postdoctural Training

Interventional Cardiology

  • 7/97 – 6/98: Post-Doctoral Clinical Fellow, Department of Medicine, Division of Cardiology, Mount Sinai Medical Center, New York, NY

Fellowship

  • 7/94 – 6/97: Clinical Assistant Physician, Department of Medicine, Division of Cardiology, Columbia Presbyterian Medical Center, New York, NY
  • 7/94 – 6/97: Assistant in Clinical/Post-Doctoral Clinical Fellow, Columbia University College of Physicians and Surgeons, New York, NY

Internship and Residency

  • 7/91 – 6/94: Intern and Resident (PGY 1-3), Department of Medicine, Columbia Presbyterian Medical Center, New York, NY
  • 7/91 – 6/94: Post-Doctoral Residency Fellow in Medicine, Columbia University, College of Physicians and Surgeons, New York, NY

Licensure and Certification

  • 2000: Virginia State Medical License #0101226688, Expiration: 5/31/2020
  • 2000 – Present: Diplomat, American Board of Internal Medicine, Interventional Cardiology
  • 1999: Licensure, Nuclear Cardiology
  • 1995: Diplomat, American Board of Internal Medicine, Cardiovascular Diseases
  • 1992: Diplomat, National Board of Medical Examiners

Professional Organizations

  • Fellow, American College of Cardiology
  • Fellow, Society of Coronary Angiography and Intervention

Awards and Honors

  • 1987: BA in Biochemistry, Cum Laude, New York University
  • 1987 – 1991: Silverstein Scholarship Award, New York University School of Medicine

Research Experience

2017

Principle Investigator, NHLBI LAMPOON , intentional laceration of the anterior mitral leaflet to prevent left ventricular outflow tract obstruction during transcatheter mitral valve implantation.

Principle Investigator, Evaluation of Transcatheter Aortic Valve Replacement Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis EARLY TAVR.

Principle Investigator, Transcatheter Mitral Valve Replacement with the Medtronic IntrepidTM TMVR System in patients with severe symptomatic mitral regurgitation – APOLLO Trial.

2016

Principle Investigator, The Partner 3 Trial- Safety and effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis.

Principal Investigator, Transcaval Aortic Valve Replacement Registry (NIH).

Principal Investigator, GALILEO: Comparing Rivaroxaban to antiplatelet based strategy after TAVR. (Bayer Healthcare).

Sub-Investigator, PHP Shield II: Cardiopulmonary support in complex PCI. (St. Jude Medical).

2015

Sub-Investigator, THEMIS: Evaluating the effect of Ticagrelor vs. placebo on the incidence of CV Death, MI, or CVA in patients with T2DM (Astra Zeneca)(RAVE).

Sub-Investigator, TI-PAD: Ticagrelor vs. Aspirin in Ambulatory patients with PAD ABI <0.9(Astra Zeneca) (Datatrak).

2014

Principle Investigator. PARACHUTE. Parachute Ventricular Restoration in Chronic Heart Failure due to Ischemic Heart Disease (Cardio Kinetix Inc).

Sub-Investigator, TIMI 61 CAMELLIA. Evaluating the safety and efficacy of Lorcaserin (Belviq) a weight loss drug in patients at high-risk for cardiovascular events (Eisai).

Sub-Investigator, PRADAXA GI. Evaluating the gastrointestinal symptoms of patients when taking Pradaxa with food or pantoprazole (Protonix) vs. an empty stomach. (Boehringer Ingelheim).

2013

Principal Investigator, DECLARE—TIMI 58. To Evaluate the effect of Dapagliflozin on Cardiovasclar Events ( Astra Zeneca and Bristol Myers Squibb).

Principal Investigator, ODYSSEY. To evaluate the effectiveness of an antibody to impair PCSK9 function resulting in lower LDL. Sanofi and DCRI.

Sub-Investigator, EXCEL, The evaluation of Xience Prime or Xience 4 versus Coronary Artery Bypass Surgery for effectiveness of left main revascularization. Sponsor: Abbott.

Co-Investigator, ABSORB BVS, The Everolimus Eluting Bioresorbable vascular scaffold in the treatment of subjects with De Novo native coronary artery lesions. Sponsor: Abbott.

Sub-Investigator, PIONEER AF-PCI. Treatment Strategies with Rivaroxaban (Xeralto) vs. Warfarin in patients with AF who undergo PCI (Janssen).

Sub-investigator, ENDEAVOR, A clinical evaluation of the Zotarolimus-Eluting Coronary stent system in the treatment of De Novo lesions in native coronary arteries with a reference vessel diameter of 2.25mm to 4.2mm. Sponsor: Medtronic.

Sub-Investigator, COREVALVE, To evaluate the safety and efficacy of the Medtronic CoreValve System in the treatment of symptomatic severe aotic stenosis in subjects who have a predicted high risk for aortic valve surgery. Sponsor: Medtronic.

Sub-Investigator, EUCLID Sponsor: AstraZeneca and DCRI. Comparing ticagrelor with clopidogrel tt on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established PAD.

Sub-Investigator, CIRT. NIH Cardiovascular Inflammation Reduction Trial using low-dose methotrexate (LDM) in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with type 2 diabetes.

2012

Sub-Investigator, “Accent MRI pacemaker and Tendril MRI Lead IDE Study” – St. Jude Medical.

Principal Investigator, EXAMINE. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome. Takeda.

Sub-Investigator, REDUCE-IT. To Evalulate the effect of AMR101 on Cardiovascular health and Mortality in Hypertriglyceridemic patients with CV disease or at High Risk for CV disease. Amarin.

2011

Sub-Investigator, REVEAL—TIMI 55. To determine the clinical effects of anacetrapib among people with established vascular disease. Merck/ Brigham and Women’s Hospital/University of Oxford.

Principal Investigator, ALERTS, for Early Recognition of STEMI. Angel Medical Guardian System.

2010

Sub-Investigator, Astra Zeneca PEGASUS – TIMI 54. Evaluation of long-term efficacy and safety of Ticagrelor in patients with history of Myocardial Infarction from one to three years prior to enrollment. Astra Zeneca and the TIMI Study Group.

Principal Investigator, SAVOR-TIMI 53 –“Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus’. Astra Zeneca and the TIMI Study Group.

2009

Sub-investigator, TRILOGY “A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) subjects with Unstable Angina(UA)/Non-ST-elevated Myocardial Infarction (NSTEMI) who are medically managed. Eli Lilly and Duke Clinical Research Institute.

Sub-investigator DAL-OUTCOMES “To evaluate the effects of dalcetrapib on CV risk in stable CHD patients with a documented recent Acute Coronary Syndrome”. Roche and Mayo Clinic.

Sub-investigator, TRA2P-TIMI 50 – ‘Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events’. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease. Schering Plough and the Timi Study Group.

Sub-investigator, APPRAISE 2- “Apixaban for Prevention of Acute ischemic Events.’ A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban n Subjects with a Recent Acute Coronary Syndrome. Brisol-Myers-Squibb and Duke Clinical Research Institute.

2008

Sub-investigator Sanofi Aventis SEPIA/ACS (TIMI 42/A) A randomized, double-blind, triple-dummy, dose-ranging study, including an active control of unfractionated heparin and eptifibatide, to evaluate the clinical efficacy and safety of otamixaban, in patients with non-ST elevation acute coronary syndrome and planned early invasive strategy-Phase 2B at Inova Fairfax Hospital.

2006

Sub-investigator, The ENDEAVOR IV Trial: A Randomized, Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesion, Inova Fairfax Hospital.

2003

Sub-investigator, ACUITY trial, A randomized comparison of Angiomax® (bivalirudin) versus heparin (enoxaparin or unfractionated heparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation-(Phase IV) at Inova Fairfax Hospital.

2002

Sub-investigator, SYNERGY, A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndrome (ACS) (Phase IV), Inova Fairfax Hospital.

Publications

    1. Shahram Yazdani, MD, Alan D. Simon, MD., Weizheng Wang, MD, Allan Schwartz, MD, Leroy E. Rabbani, MD. PERCUTANEOUS INTERVENTIONS ALTER THE INFLAMMATORY PROFILE IN UNSTABLE ANGINA VERSUS STABLE ANGINA. Am Heart J. 1998;136:357- 61
    2. Nader Moazami, MD, Michael Argenziano, MD, Takushi Kohomoto, MD, Shahram Yazdani, MD, Howard Levin, MD, Eric A. Rose, MD, Mehet C. Oz, MD, Daniel Burkhoff, MD. INFLOW VALVE REGURGITATION DURING LVAD SUPPORT INTERFERES WITH REVERSE VENTRICULAR REMODELING. Ann Thorac Sur. Mar 1998,65(3) 625-37
    3. Shahram Yazdani, MD, Alan D. Simon, MD, Weizheng Wang, MD, Allan Schwartz, MD, LeRoy E. Rabbani, MD. PERCUTANEOUS INTERVENTIONS ALTER THE HEMOSTATIC PROFILE IN UNSTABLE ANGINA VERSUS STABLE ANGINA. J Am Coll Cardiol. 1997;30:1284-7
    4. Weizheng Wang, MD, Hong Jun Chen MD, Shahram Yazdani, MD, Alan Simon, MD, Allan Schwartz, MD, LeRoy E. Rabbani, MD. INTERLEUKIN-4 MODUATION OF PLATELET-DERIVED GROWTH FACTOR-INDUCED S M O O T H MUSCLE CELL UROKINASE PLASMINOGEN ACTIVATOR. J Thrombolysis thrombosis.
    5. Mical Campbell, Allan Schwartz, MD, C.A. Stein, MD, LeRoy E. Rabbani, MD. LENGTH DEPENDENCE OF PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES ON THE NON-SEQUENCE SPECIFIC INHIBITORY EFFECTS OF IN VITRO VASCULAR SMOOTH MUSCLE CELL PROLIFERATION AND MIGRATION. J Am Coll Cardiol. 1997;(29,Suppl.):243A
    6. Alan D. Simon, MD, Shahram Yazdani, MD, Weizheng Wang, MD, Allan Schwartz, MD, LeRoy E. Rabbani, MD. INFLAMMATORY CYTOKINES IN STABLE VERSUS UNSTABLE ANGINA. J. Am Coll Cardiol. 1997;(29,Suppl.):233A
    7. Shahram Yazdani, MD, Lance I. Kovar, MD, Alan D. Simon, MD, Weizheng Wang, MD, Carolyn Gulotta, RN, Allan Schwartz, MD, LeRoy E. Rabbani, MD, SERIAL HEMOSTATIC FACTOR MEASUREMENTS IN CORONARY INTERVENTIONS FOR STABLE VERSUS UNSTABLE ANGINA. J Am Coll Cardiol. 1997;(29, Suppl.):12A
    8. Alan D. Simon, MD, Shahram Yazdani, MD, Weizheng Wang, MD, Allan Schwartz, MD, LeRoy E. Rabbani, MD. T-CELL LYMPHOKINES IN STABLE AND UNSTABLE ANGINA. Europ Cytokine Network 1996;7(3):632
    9. Alan D. Simon, MD, Shahram Yazdani, MD, Weizheng Wang, MD, Allan Schwartz, MD, LeRoy E. Rabbani, MD. MARKERS OFT LYMPHOCYTE ACTIVATION ARE ELEVATED IN STABLE ANGINA BUT NOT IN UNSTABLE ANGINA. Circulation. 1996; 94(8, Suppl.): I81
    10. Stuart D. Katz, MD, Gregory Koshkarian, MD, Rochelle L. Goldsmith, PhD, Randolph P. Cole, MD, Gregory A. DeLong, BS, Shahram Yazdani, MD, Milton Packer, MD, FACC. IMPAIRED VENTILATORY ADAPTATIONS TO SUBMAXIMAL EXERCISE IN PATIENTS WITH CHRONIC HEART FAILURE. J Am Coll Cardiol. 1995;(25,Suppl.): 266A